Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tenaya TherapeuticsTNYA -1.91%30 PS Ratio is 109.62 as of Sep. 16, 2026, which is 84% below its 10-year median of 681.10. GuruFocus rates TNYA with a GF Score™ of 30/100. The stock has 4 warning signs investors should review. Among 939 Biotechnology companies, Tenaya Therapeutics ranks worse than 85.62% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Tenaya Therapeutics's share price is $0.6577.
Tenaya Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was $0.01. Hence, Tenaya Therapeutics's PS Ratio for today is 109.62.
Good Sign:
Tenaya Therapeutics Inc stock PS Ratio (=106.67) is close to 1-year low of 106.67.
The historical rank and industry rank for Tenaya Therapeutics's PS Ratio or its related term are showing as below:
TNYA'
s PS Ratio Range Over the Past 10 Years
Min: 106.67 Med: 681.1 Max: 1000
Current: 109.91
During the past 7 years, Tenaya Therapeutics's highest PS Ratio was 1000.00. The lowest was 106.67. And the median was 681.10.
TNYA's PS Ratio is ranked worse than 85.62% of 939
companies
in the Biotechnology industry
Industry Median: 9.21
vs TNYA: 109.91
Tenaya Therapeutics (NAS:TNYA) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Tenaya Therapeutics PS Ratio Related Terms
Tenaya Therapeutics PS Ratio Historical Data
* Premium members only.
The historical data trend for Tenaya Therapeutics's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Tenaya Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tenaya Therapeutics PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Tenaya Therapeutics's PS Ratio distribution charts can be found below:
* The bar in red indicates where Tenaya Therapeutics's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Tenaya Therapeutics's Share Price of today is $0.6577. Tenaya Therapeutics's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.01.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Tenaya Therapeutics (TNYA) has a PS Ratio of 109.62 as of Sep. 16, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Tenaya Therapeutics and its competitors. This is 84% below median its historical median of 681.10. Over the past decade, Tenaya Therapeutics' PS Ratio has ranged from 106.67 to 1,000.00. According to the industry distribution chart, Tenaya Therapeutics ranks #804 out of 939 companies in the Biotechnology industry, placing it in the top 85.6%.
Is Tenaya Therapeutics' PS Ratio too high?
Tenaya Therapeutics' current PS Ratio of 109.62 is 84% below median its 10-year median of 681.10. Over the past 10 years, this metric has ranged from a low of 106.67 to a high of 1,000.00. The Biotechnology industry median PS Ratio is 9.21. Tenaya Therapeutics' value of 109.62 is 1090.2% above this industry median. Based on the distribution chart, Tenaya Therapeutics ranks #804 out of 939 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Tenaya Therapeutics has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Tenaya Therapeutics' PS Ratio compare to OKUR and INDP?
According to the Biotechnology industry distribution chart, Tenaya Therapeutics ranks #804 out of 939 companies for PS Ratio. This places Tenaya Therapeutics in the lower half of its industry. The industry median PS Ratio is 9.21. Tenaya Therapeutics' value of 109.62 is 1090.2% above this benchmark. Historically, Tenaya Therapeutics' own PS Ratio has ranged from 106.67 to 1,000.00 over the past decade. While the company's 10-year median is 681.10 vs. the industry median of 9.21, Tenaya Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.21, based on 939 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tenaya Therapeutics's current PS Ratio of 109.62 is 1090.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Tenaya Therapeutics and its competitors. For the Biotechnology industry, the median PS Ratio is 9.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tenaya Therapeutics's current PS Ratio is 109.62, which is 84% below median its own 10-year median of 681.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tenaya Therapeutics stock overvalued right now?
Tenaya Therapeutics (TNYA) has a current PS Ratio of 109.62. The current PS Ratio is 109.62, which is 84% below median its 10-year median of 681.10 and 1090.2% above the Biotechnology industry median of 9.21. Tenaya Therapeutics' overall GF Score™ is 30/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Tenaya Therapeutics (TNYA), the current PS Ratio is 109.62 as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.
30GF Score
Get the complete analysis for TNYA
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TNYA has been successfully added to your 
